Latest Hotspot

EU Approves Pfizer's VELSIPITY® for Moderate to Severe Ulcerative Colitis

23 February 2024
3 min read

Pfizer Inc. has revealed that the European Commission has approved VELSIPITY® (etrasimod) for distribution within the European Union. This approval allows the treatment to be used for individuals aged 16 and above who are experiencing moderate to severe ulcerative colitis and have not responded well to standard treatment, have ceased responding, or cannot tolerate previous therapeutic options, including biological treatments.

👇Explore more about this drug by clicking the image below. Gain detailed insights into its R&D Status, Core Patent, Clinical Trials and Global Approval Status. Stay informed and updated.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Approximately 2.6 million individuals in Europe grapple with the challenges of ulcerative colitis (UC), facing a spectrum of fluctuating physical and psychological difficulties that can be severely incapacitating. Many engage in a trial-and-error process with various standard treatments in an effort to alleviate their distressing symptoms, explained Séverine Vermeire, MD, PhD, a Medicinal Professor at KU Leuven and a primary researcher in the ELEVATE Registrational Program.

Dr. Vermeire added that the sanctioning of VELSIPITY offers a new avenue for those who live with moderate to severe forms of UC and seek powerful treatments beyond traditional options, but who might be reluctant to adopt injectable biologic therapies.

VELSIPITY has received marketing clearance across all 27 European Union countries and has expanded to include Iceland, Liechtenstein, and Norway. This clearance comes on the heels of the European Medicines Agency’s Committee for Medicinal Products for Human Use endorsement in December 2023.

Previous approvals for VELSIPITY for moderate to severe UC in adult patients by the U.S. Food and Drug Administration in October 2023, as well as the Canadian authorization in January 2024 for adults with an unsatisfactory response or intolerance to conventional or other advanced therapies, pave the way for this EU authorization. Moreover, regulatory filings for VELSIPITY's usage in UC are currently under review in several other nations worldwide.

Alexandre de Germay, Pfizer's Chief International Commercial Officer and Executive Vice President, highlighted that VELSIPITY may provide an advantage for patients with UC who have not attained remission through traditional therapies. He emphasized its convenient single daily oral dose and a positive balance of benefits and risks. According to de Germay, VELSIPITY represents a promising treatment possibility, and Pfizer is committed to delivering it to eligible UC patients, starting at 16 years of age, throughout the European market.

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click! 

图形用户界面, 文本, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of February 23, 2024, there are 3 investigational drugs for the S1PR1 and S1PR4 and S1PR5 target, including 19 indications,16 R&D institutions involved, with related clinical trials reaching 168, and as many as 439 patents.

VELSIPITY is a once-daily, oral, sphingosine 1-phosphate (S1P) receptor modulator that selectively binds with S1P receptor subtypes 1, 4, and 5. Its approval and potential launch in the coming years will likely contribute to advancements in the treatment of digestive system disorders, immune system diseases, congenital disorders, and skin/musculoskeletal diseases.

图形用户界面, 文本

描述已自动生成

Exploring Disitamab Vedotin's R&D successes and its clinical results at the 2024 ASCO_GU
Exploring Disitamab Vedotin's R&D successes and its clinical results at the 2024 ASCO_GU
23 February 2024
The latest ASCO_GU 2024 update summarized new clinical findings on disitamab vedotin and toripalimab as an innovative neoadjuvant therapy for HER2+ advanced local MIBC patients.
Read →
FDA Endorses Xolair as the Sole Treatment for Food Allergies in Both Kids and Grown-ups
Latest Hotspot
3 min read
FDA Endorses Xolair as the Sole Treatment for Food Allergies in Both Kids and Grown-ups
23 February 2024
Genentech announced that the US FDA has approved Xolair (omalizumab) for reducing allergic reactions.
Read →
Your Ultimate Guide to Finding Diclofenac sodium on Synapse
Drug Insights
2 min read
Your Ultimate Guide to Finding Diclofenac sodium on Synapse
23 February 2024
Diclofenac sodium, a benzene-acetic acid derivative, is a nonsteroidal anti-inflammatory drug (NSAID) ,has analgesic, anti-inflammatory, and antipyretic properties.
Read →
US Approves TAGRISSO® and Chemotherapy Combo for Advanced EGFR-Mutated Lung Cancer
Latest Hotspot
3 min read
US Approves TAGRISSO® and Chemotherapy Combo for Advanced EGFR-Mutated Lung Cancer
23 February 2024
US authorities greenlight a combined treatment of TAGRISSO® (osimertinib) and chemotherapy for individuals battling advanced lung cancer with EGFR mutations.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.